QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ABVX

QT69Abivax S.A.
NASDAQ·Healthcare·Biotechnology·FR
Latest market price
99.15
-1.00-1.00%
OverviewShort InterestFilings
ABVXQT69Abivax S.A.·NASDAQ
OverviewShort InterestFilings
99.15-1.00%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-7.44
Insider Own-
Shs Outstand79.69M
Perf Week-1.71%
Market Cap8.03BForward P/E-EPS next Y-3.46Insider Trans-Shs Float-Perf Month-12.82%
Enterprise Value7.49BPEG0.30EPS next Q-1.01Inst Own-Short Float-Perf Quarter-19.41%
Income-442507321.00P/S0.00EPS this Y60.43%Inst Trans-Short Ratio-Perf Half Y-10.66%
Sales-P/B13.41EPS next Y-17.64%ROA-57.52%Short Interest-Perf YTD-26.47%
Book/sh6.71P/C-EPS next 5Y-ROE-165.19%52W High148.83 -33.38%Perf Year1536.14%
Cash/sh7.82P/FCF-EPS past 3/5Y-ROIC-45.51%52W Low5.69 1642.53%Perf 3Y-
Dividend Est.-EV/EBITDA-26.18Sales past 3/5Y-Gross Margin0.00%Volatility4.31% 12.78%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-43.00%Oper. Margin0.00%ATR (14)8.46Perf 10Y-
Dividend Ex-Date-Quick Ratio8.75Sales Y/Y TTM-Profit Margin0.00%RSI (14)43.76Recom2.22
Dividend Gr. 3/5Y-Current Ratio8.75EPS Q/Q63.51%SMA20-8.10%Beta3.82Target Price132.00
Payout0.00%Debt/Eq0.10Sales Q/Q-100.00%SMA50-13.28%Rel Volume0.95Prev Close100.15
Employees69LT Debt/Eq0.07EarningsSep 14SMA200-10.66%Avg Volume1.78MPrice99.15
IPO DateOct 20, 2023Option/ShortYes / YesEPS/Sales Surpr.24.39% -Net Debt/EBITDA1.89Volume1,697,522Change-1.00%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-03-26ReiteratedWolfe Research$176 → $136
Jun-02-26ReiteratedTruist Financial$140 → $135
Jun-02-26DowngradeJefferiesBuy → Hold$90
Jun-02-26ReiteratedMorgan StanleyOverweight$145 → $132
Jun-02-26UpgradeWedbushUnderperform → Neutral$110 → $90
Feb-24-26InitiatedWedbushNeutral$110
Jan-09-26ReiteratedMorgan StanleyOverweight$12 → $145
Jan-08-26ReiteratedOppenheimer$131
Jan-08-26ReiteratedBTIGBuy$120 → $150
Dec-18-25ReiteratedGuggenheimBuy$150 → $175
Latest News
Jun-18-26
Jun-18-2606:53AM
Abivax: Safety Signals Loom Ahead Of The NDA SubmissionSeekingAlpha
Jun-16-26
Jun-16-2605:39AM
BTIG Reiterates Buy on Abivax, Maintains $150 Price TargetBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue
900
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A000
Gross Profit900
Selling, General and Administrative Excl. Other378242
Research and Development162201159
Other Operating Expense12-5-14
Operating Income-203-278-187
Interest Expense263213
Unusual Expense
———
Non-Operating Income (Expense)-1563-10
Net Income Before Taxes-242-373-191
Income Taxes-870
Consolidated Net Income-233-379-191
Net Income From Continuing Operations-233-379-191
Net Income-233-379-191
EPS (Recurring)-7.44-5.25-3.03
EPS (Basic, Before Extraordinaries)-7.44-5.25-3.03
EPS (Diluted)-7.44-5.25-3.03
EBITDA-195-339-176
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
528.80——
Gross Margin
100.00——
Operating Margin
-2,255.56——
Net Margin
-2,588.89——
Shares Outstanding487063
Market Capitalization4,7599,440—
Operating Lease Expense
———
Insider Trading Volume
$103.94$93.57$83.20$72.83$62.46● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR